Concepedia

Andrew L. Rygiel

AL

Statistics

Publications

8

Citations

489

H-Index

8

Active since

2019

Affiliations

American Society of Clinical Oncology(Current)

Duke Medical Center

Cancer Treatment Centers of America

Levine Cancer Institute

Intermountain Healthcare

Andrew L. Rygiel is an author at American Society of Clinical Oncology specializing in pharmacology, oncology, and cancer pharmacology.

Publications per year

2019–2021

8

Publications

8

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Ajjai Alva, Pam K. Mangat, Elizabeth Garrett‐Mayer et al. · Journal of Clinical Oncology · 2021 · 182 citations

, , +17

Palbociclib in Patients With Pancreatic and Biliary Cancer With<i>CDKN2A</i>Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Tareq Al Baghdadi, Susan Halabi, Elizabeth Garrett‐Mayer et al. · JCO Precision Oncology · 2019 · 93 citations

, , +17

Palbociclib in Patients With Non–Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Eugene R. Ahn, Pam K. Mangat, Elizabeth Garrett‐Mayer et al. · JCO Precision Oncology · 2020 · 69 citations

, , +16

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Julie Gottlieb Fisher, David L. Tait, Elizabeth Garrett‐Mayer et al. · Targeted Oncology · 2020 · 47 citations

, , +17

Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Tareq Al Baghdadi, Elizabeth Garrett‐Mayer, Susan Halabi et al. · Targeted Oncology · 2020 · 43 citations

, , +12

1–5 of 8